GlobalData Plc
  • Press Release

    Takeda will be looking to Shire’s drug pipeline to bolster future sales after disappointing Q1 results

Following the announcement of a significant dip in first-quarter operating profit for Takeda, Thomas Moore, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the company’s future:

“Takeda’s first-quarter operating profits took a 49% hit year-on-year, and represent the weakest first quarter profit in the last three years. Looking to the future, the company will be hoping that its £46bn ($61bn) merger with Shire will bolster its drug pipeline and allow it to recover some of the recent drop in revenue.

“When looking at the current drugs pipeline for Takeda and Shire by peak annual sales forecast, seven of the top ten products are expected to come from Shire’s pipeline. This includes Hereditary Angioedema (HAE) monoclonal antibody, lanadelumab, which is on track to launch in the US and EU towards the end of the year, and is forecast to reach blockbuster annual sales of $1.3bn by 2023. Compared to Shire’s future offerings, Takeda’s own pipeline is looking a little bare, and so the company will be looking to leverage Shire’s pipeline once the merger has completed in order to reignite its stumbling operating profits.”

Takeda’s merger with Shire was agreed in May this year and is set to be one of the largest deals by a pharmaceutical company in history, including the largest ever takeover by a Japanese company. GlobalData predicts that once completed, the newly formed entity will be the ninth-largest pharmaceutical company in the world, based on 2017 sales.

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF